REMARKS Q The GDG noted the paucity of evidence on the balance of benefits versus harms when antenatal corticosteroids are administered to women undergoing planned caesarean section (CS) at 34 weeks 0 days to 36 weeks 6 days gestation. The GDG acknowledged that, while there might be some benefits, there might also be harms. Reference was made to the overall evidence on antenatal corticosteroids, which included women undergoing provider-initiated (planned) preterm birth, and also suggested potential harms in late preterm infants. Q The GDG considered this to be a research priority but chose to recommend against the practice until further evidence becomes available. Q The GDG reaffirms that all pre-conditions outlined for antenatal corticosteroid therapy in Recommendation 1.0 apply.

Implementation considerations outlined in Table 2.